← Back to home

AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY ENTERITIS

Clinical trials for AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY ENTERITIS explained in plain language.

Never miss a new study

Get alerted when new AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY ENTERITIS trials appear

Sign up with your email to follow new studies for AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY ENTERITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope for rare disease patients with severe gut problems

Disease control Recruiting now

This study is testing if a drug called emapalumab can help control severe intestinal inflammation in people with APECED, a rare autoimmune disease. Up to 10 participants, aged 2 to 75, will receive the drug through an IV over several months. The main goal is to see if it safely r…

Matched conditions: AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY ENTERITIS

Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control

Last updated Mar 27, 2026 12:39 UTC

AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY ENTERITIS

Get alerted when new AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY ENTERITIS trials appear

New hope for rare disease patients with severe gut problems